Oyster Point Pharma

General Information


We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Our lead product candidate OC-01 (varenicline), a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease (DED). OC-01’s novel mechanism of action is designed to re-establish tear film homeostasis by activating the trigeminal parasympathetic pathway and stimulating the glands and cells responsible for natural tear film production. In our Phase 2b clinical trial (ONSET-1) in 182 subjects, OC-01 demonstrated statistically significant improvements (as compared to placebo) in both signs and symptoms of DED in a single registrational clinical trial—we are not aware of any other therapy that has accomplished this in a single registrational clinical trial. Based on OC-01’s clinical trial results and its rapid onset of action, we believe OC-01, if approved, has the potential to become the new standard of care and redefine how DED is treated for millions of patients. We initiated a Phase 3 clinical trial (ONSET-2) in July 2019 and expect to report top-line results in mid-2020.

Employees: 18
Founded: 2015
Contact Information
Address 202 Carnegie Center, Suite 109, Princeton, NJ 08540, US
Phone Number (609) 382-9032.
Web Address http://www.oysterpointrx.com
View Prospectus: Oyster Point Pharma
Financial Information
Market Cap $329.8mil
Revenues $0 mil (last 12 months)
Net Income $-25.1 mil (last 12 months)
IPO Profile
Symbol OYST
Exchange NASDAQ
Shares (millions): 5.0
Price range $16.00 - $16.00
Est. $ Volume $80.0 mil
Manager / Joint Managers J.P. Morgan/ Cowen and Company/ Piper Jaffray
CO-Managers -
Expected To Trade: 10/31/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change